GSK, Vivalis get green light to test new vax tech

The push to get better, faster vaccine technology in place took a step forward with the news that France's Vivalis and GlaxoSmithKline have won FDA approval to begin clinical trials of a new flu jab using duck stem cell line EB66 technology. Vivalis says the regulatory green light could pave the way to an approval for the first such new vaccine as early as 2015. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.